MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on July 26, 2018, 03:51:15 pm

Title: (Abst.) Efficacy and safety of ozanimod in MS
Post by: agate on July 26, 2018, 03:51:15 pm
"Efficacy and safety of ozanimod in multiple sclerosis:  Dose-blinded extension of a randomized Phase II study" by  from PubMed, July 26, 2018:


https://www.ncbi.nlm.nih.gov/pubmed/30043658
Title: (Abst.) Ozanimod vs. IFN beta-1a in Phase 3 RADIANCE trial
Post by: agate on September 08, 2019, 04:13:40 pm

Abstract of an article in The Lancet (September 3, 2019), "Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial":

https://www.ncbi.nlm.nih.gov/pubmed/31492652
Title: (Abst.) Ozanimod vs. IFN beta-1a in Phase 3 SUNBEAM trial
Post by: agate on September 08, 2019, 04:17:59 pm
Abstract of an article in The Lancet (September 3, 2019) about a different trial  (see previous post) involving ozanimod and interferon beta-1a--"Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (SUNBEAM):  A multicentre, randomised, minimum 12-month, phase 3 trial":


https://www.ncbi.nlm.nih.gov/pubmed/31492651